Rigel Pharmaceuticals (RIGL) Q4 2023 earnings summary

Executive summary

• FY23 net product sales rose 36% to $104.3M; total revenue was $116.9M and net loss was $25.1M.

• U.S. GAVRETO rights were acquired in February 2024, with sales recognition expected to begin in Q3 2024.

Financial highlights

• FY23 revenue was $116.9M versus $120.2M in FY22; net product sales were $104.3M versus $76.7M, while collaboration revenue was $11.5M versus $39.0M.

• Q4 2023 revenue was $35.8M versus $51.3M; net income was $0.7M, or $0.00/share, versus $1.4M, or $0.01/share.

• FY23 operating loss was $20.5M versus $55.6M; net loss was $25.1M, or $0.14/share, versus $58.6M, or $0.34/share.

• Cash, cash equivalents and short-term investments totaled $56.9M at year-end 2023, versus $58.2M at year-end 2022.

Outlook and guidance

• 2024 priorities include commercial expansion, growing TAVALISSE and REZLIDHIA sales, advancing the pipeline, strategic collaborations and financial discipline.

• GAVRETO transition and patient transfers are expected to finish in Q3 2024, with broader prescriber outreach continuing in Q4.

• Development plans include olutasidenib in AML, MDS and glioma, enrolling the R289 Phase 1b lower-risk MDS study, and pursuing late-stage in-licensing opportunities.